These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18668369)

  • 1. Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication.
    Wallack SS; Thomas CP; Martin TC; Chilingerian J; Reif S
    J Behav Health Serv Res; 2010 Jan; 37(1):64-78. PubMed ID: 18668369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.
    Andrews CM; D'Aunno TA; Pollack HA; Friedmann PD
    Med Care Res Rev; 2014 Feb; 71(1):43-60. PubMed ID: 24051897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State policy influence on the early diffusion of buprenorphine in community treatment programs.
    Ducharme LJ; Abraham AJ
    Subst Abuse Treat Prev Policy; 2008 Jun; 3():17. PubMed ID: 18570665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.
    Savage SA; Abraham AJ; Knudsen HK; Rothrauff TC; Roman PM
    J Subst Abuse Treat; 2012 Jan; 42(1):16-24. PubMed ID: 21831565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial.
    Molfenter T; Kim JS; Quanbeck A; Patel-Porter T; Starr S; McCarty D
    Implement Sci; 2013 May; 8():50. PubMed ID: 23663749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.
    Friedmann PD; Jiang L; Alexander JA
    J Behav Health Serv Res; 2010 Jul; 37(3):322-37. PubMed ID: 19296223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors.
    Knudsen HK; Ducharme LJ; Roman PM; Link T
    J Subst Abuse Treat; 2005 Sep; 29(2):95-106. PubMed ID: 16135338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors.
    Knudsen HK; Ducharme LJ; Roman PM
    J Subst Abuse Treat; 2006 Jun; 30(4):363-73. PubMed ID: 16716852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
    Knudsen HK; Abraham AJ; Johnson JA; Roman PM
    J Subst Abuse Treat; 2009 Oct; 37(3):307-12. PubMed ID: 19577406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.
    Rieckmann TR; Kovas AE; McFarland BH; Abraham AJ
    J Subst Abuse Treat; 2011 Dec; 41(4):374-85. PubMed ID: 21821379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community treatment programs take up buprenorphine.
    Casadonte PP; Kolodner GF; Horton T; McMurphy SM
    Sci Pract Perspect; 2004 Aug; 2(2):24-9. PubMed ID: 18552729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.
    Heinrich CJ; Cummings GR
    Health Serv Res; 2014 Feb; 49(1):127-52. PubMed ID: 23855719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
    Koch AL; Arfken CL; Schuster CR
    Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
    Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network.
    Roman PM; Abraham AJ; Rothrauff TC; Knudsen HK
    J Subst Abuse Treat; 2010 Jun; 38 Suppl 1():S44-52. PubMed ID: 20307795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption.
    Ducharme LJ; Roman PM
    J Subst Abuse Treat; 2009 Jul; 37(1):90-4. PubMed ID: 19004597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.
    Knudsen HK; Abraham AJ
    Psychiatr Serv; 2012 Jan; 63(1):19-25. PubMed ID: 22227755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
    Yang JC; Roman-Urrestarazu A; Brayne C
    PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.